Lataa...
Contraindications to intravenous rtPA for acute stroke: A critical reappraisal
Only 1%–5% of patients with acute ischemic stroke presenting within 3 hours of symptoms receive IV recombinant tissue plasminogen activator (rtPA)—the only effective treatment available. The administration of rtPA is limited by extensive exclusion criteria, many of which are not based on evidence, b...
Tallennettuna:
| Julkaisussa: | Neurol Clin Pract |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Academy of Neurology
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5798502/ https://ncbi.nlm.nih.gov/pubmed/29473642 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/CPJ.0b013e318296f0a9 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|